MedTrace Logo

Reparixin in Pancreatic Islet Transplantation

NCT01220856 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-03-11

Study results available
· View outcomes & findings →

Summary

Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor of CXCL8. This study is designed to explore the efficacy of reparixin in preventing graft dysfunction after islet transplantation in type 1 diabetes patients (T1D).

Conditions

  • Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus

Interventions

DRUG

Reparixin

Reparixin + immunosuppression

Sponsors & Collaborators

  • Dompé Farmaceutici S.p.A

    lead INDUSTRY

Principal Investigators

  • Lorenzo Piemonti, MD · Fondazione Centro San Raffaele del Monte Tabor - Milan; Italy

  • Barbara Ludwig, MD · University Hospital Carl Gustav Carus - Dresden; Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-28
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01220856 on ClinicalTrials.gov